Published in final edited form as:

Pain. 2013 December ; 154 Suppl 1: . doi:10.1016/j.pain.2013.05.037.

The fundamental unit of pain is the cell

David B. Reichling, Paul G. Green, and Jon D. Levine*

Department of Medicine, Division of Neuroscience, University of California–San Francisco, San Francisco, CA, USA. Department of Oral and Maxillofacial Surgery, Division of Neuroscience, University of California–San Francisco, San Francisco, CA, USA

Abstract

The molecular/genetic era has seen the discovery of a staggering number of molecules implicated in pain mechanisms [18,35,61,69,96,133,150,202,224]. This has stimulated pharmaceutical and biotechnology companies to invest billions of dollars to develop drugs that enhance or inhibit the function of many these molecules. Unfortunately this effort has provided a remarkably small return on this investment. Inevitably, transformative progress in this field will require a better understanding of the functional links among the ever-growing ranks of “pain molecules,” as well as their links with an even larger number of molecules with which they interact. Importantly, all of these molecules exist side-by-side, within a functional unit, the cell, and its adjacent matrix of extracellular molecules. To paraphrase a recent editorial in *Science* magazine [223], although we live in the Golden age of Genetics, the fundamental unit of biology is still arguably the cell, and the cell is the critical structural and functional setting in which the function of pain-related molecules must be understood. This review summarizes our current understanding of the nociceptor as a cell-biological unit that responds to a variety of extracellular inputs with a complex and highly organized interaction of signaling molecules. We also discuss the insights that this approach is providing into peripheral mechanisms of chronic pain and sex dependence in pain.

Keywords

Cell biology; Extracellular matrix; Mitochondrion; Chronic pain; Neuroplasticity

1. The nociceptor: a model cell

Among the earliest studies of the cell biology of pain were those performed by Perl and colleagues, starting nearly a half century ago [21,39,186,186]. Their work provided the fundamental insight that different nociceptors respond to different forms of noxious stimulation (ie, mechanical, thermal, and diverse chemicals), alone or in various combinations [186,221], those responding to multiple sensory modalities of noxious stimuli being referred to as polymodal nociceptors [157,185,188,205]. These studies introduced the critically important concept that primary afferent nociceptors are a heterogeneous group of cells that contribute to different forms of pain. It was not, however, until several decades later, that we began to elucidate the molecular basis of the transduction processes of these different forms of noxious stimuli. Although there remain gaps in our knowledge of the

© 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

*Corresponding author at: Department of Oral & Maxillofacial Surgery, Box 0440, University of California–San Francisco, San Francisco, CA 94143-0440, USA. Tel.: +1 415 476 5108; fax +1 415 476 6305. Jon.Levine@ucsf.edu (J.D. Levine).

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Conflict of interest statement

The authors report no conflict of interest.

molecular identity of transducers for various forms of noxious stimuli, and even of which cells in each tissue the transducers are located, considerable progress has been made in our understanding of nociceptor transduction mechanisms [24,68,90,105,108].

For thermal transduction, the transient receptor potential (TRP) family of ligand-gated ion channels composes a group of transducing ion channels that gate at different temperatures, some in the noxious range [171,203,212,232]. This class of ion channels has been demonstrated to be present in sensory neurons that express other features of nociceptors (eg, expression of neuropeptides and specific types of sodium channels) [17,183,241]. However, TRP channels are not the only transducers implicated in detecting noxious thermal stimuli [49,170,182,190].

TRP channels [89,102,238] have also been implicated in transduction of noxious chemical stimuli, as have acid sensing ion channels (ASICs) [101,240]. A large number of other ligand-gated ion channels and G-protein–coupled receptors also contribute to chemical nociception, including ion channels for detection of hydrogen ions (acid, low pH) [24,25,119]; TRPA1, which responds to multiple noxious chemical substances [70,137,210]; ligand-gated ion channels (P2X) and G-protein–coupled (P2Y) receptors that detect purines [138,163,230]; and G-protein–coupled receptors for prostaglandins, the target of a major class of analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs) [56,122], to name only a small number of a still-growing list of transducers for noxious chemical stimuli. Of note, progress has recently been made in studying the most recalcitrant sensory modality in the primary afferent nociceptor—mechanical transduction—with the recent identification of Piezos by Patapoutian and colleagues [54]. Some transducers respond to stimuli of more than 1 sensory modality; the most well studied being TRPV1, the “capsaicin receptor,” which responds to heat and low pH, as well as to the noxious component of the chili pepper, capsaicin [42,220], and recently evidence has been presented to suggest that it may even play a role in mechanical transduction [126,140,231]. Similarly, TRPA1 is considered to be a transducer for many noxious irritant substances [70,87,103].

The populations of nociceptors that contain various transducers terminate in different lamina of the spinal cord and at different depths in tissues, such as the skin [33,52,150,211,214,251], providing further support for the suggestion that they define groups of nociceptors that play very different roles in the cell biology of pain [32–34,68,154,193,217]. Although most of these transducers appear to be located on the peripheral terminals of primary afferent nociceptors, recent findings suggest that some may actually be located on non-neuronal cells, which in turn release mediators that signal to the nociceptor. The best-studied cell, in this regard, is the keratinocyte [134,204,235]. Although the most compelling evidence for a role of keratinocytes in sensory transduction relates to the detection of non-noxious warmth [51,192], keratinocytes contain transducers for a variety of noxious stimuli, for example, TRPV1 and TRPA1 [13,74,109]. The potential importance of this indirect transduction mechanism in peripheral pain mechanisms is currently being investigated.

A second, unique, dimension of the function of the primary afferent nociceptor is its ability to be sensitized—that is, to undergo a decrease in threshold for activation as well as enhanced response to a stimulus of the same intensity. Sensitization is thought to play an important role in diverse pain syndromes, both inflammatory and neuropathic [26,65,76,78,114,115,117,118,179–181,194]. Sensitization in the primary afferent nociceptor contrasts with the function of sensory neurons that transduce other somatic (eg, touch, tickle, pressure) and special (eg, vision, taste, smell, and hearing) sensory modalities in that repeated stimulation tends to desensitize those neurons [85,120,128,142,168,198]. A large number of studies of nociceptor sensitization have elucidated the role of 2 classic

second messenger signaling pathways in which cAMP/protein kinase A (PKA) and protein kinase C (PKC) play key roles [6,46,48,64,162,179,194,237]. As it is beyond the scope of this review to trace in detail the second messenger signaling pathways involved in nociceptor sensitization, the reader is referred to reviews that develop this aspect of the cell biology of the nociceptor in more detail [194].

The targets of these second messenger signaling pathways, for the most part voltage- and ligand-gated ion channels, have also been studied in detail. Thus, multiple members of sodium [15,45,91,202], potassium [37,97,249], and calcium [45,144,169] ion channel families have been demonstrated to play a role in nociceptor sensitization. This can occur by phosphorylation of the channels [23,139,184,248] or by their insertion or removal from the plasma membrane [47,110,173,200,248]. One novel association between transduction and sensitization is found in a population of nociceptors that, under basal conditions, are mechanically insensitive, and are thus termed mechanically insensitive afferents [36,160] or “silent” nociceptors [88,206], but which, on exposure to inflammatory mediators, develop the ability to respond to mechanical stimulation [197,199]. Given that such mechanically insensitive afferents may play a role in some forms of pain [84,88,107], the mechanisms underlying the development of mechanical transduction of silent nociceptors on exposure to inflammatory mediators remains an important question.

It is on this historical foundation of the biology of the primary afferent nociceptor that we will discuss cell biology approaches to primary afferent nociceptor function and what they have begun to teach us about mechanisms of acute and chronic pain.

2. Contributions to pain from the extracellular environment of the nociceptor

The extracellular environment of the nociceptor relevant to the production of pain has classically been considered to consist of inflammatory mediators—cytokines and chemokines that are products of immune system cells that can sensitize nociceptors, and neurotrophic factors that, in addition to being important for the health of sensory neurons, can also contribute to the development of pain when present at elevated levels [158,172,174,189,201,202]. Of note, the observation that individual neurotrophic factors act on different populations of nociceptors has helped to establish the idea that subpopulations of nociceptors contribute to the development of specific pain syndromes. Among the earliest studies of the role of inflammatory mediators in peripheral pain mechanisms, the prostaglandins, cyclooxygenase products of arachidonic acid metabolism, were identified, and are the target of 1 of the most important and widely used classes of analgesics, NSAIDs [80,81,216,226]. Novel therapeutic possibilities for the treatment of some forms of chronic intractable pain are presented by more recently developed inhibitors (eg, cytokine and chemokine antagonists) for other inflammatory mediators that include tumor necrosis factor- α (TNF α) [2,191], interleukin 6 (IL-6) [12,40], and interleukin 1 β (IL-1 β) [177].

The first neurotrophic factor implicated in producing pain, nerve growth factor (NGF) [146,176], serves as a neurotrophin for a population of nociceptors that are also characterized by expression of the high-affinity NGF receptor, TrkA [129,148] and neuropeptides (eg, substance P and calcitonin gene-related peptide), and are thus referred to as TrkA-positive or peptidergic nociceptors [148,209,241]. The finding that NGF levels increase in the setting of inflammation [7,10,225] and nerve injury [9,141] led to the suggestion that NGF might also play a role in inflammatory and neuropathic pain [10,43,234,242]. This hypothesis has culminated in the recent demonstration that an anti-NGF antibody can be effective in the treatment of some clinical pain syndromes [38,121].

It is becoming clear that the extracellular matrix, which used to be considered little more than glue holding together the various cells in a tissue, plays a key role in the physiologic functions of cells, including the primary afferent nociceptor. For example, extracellular matrix is a ligand for a class of receptors on the cell surface, the integrins, which have the unique feature of signaling both from inside the cell out to the extracellular matrix, as well as from the extracellular environment into the cell [58,228,243]. Importantly, interrupting this signaling mechanism has been shown to affect nociceptor function. For example, blocking antibodies or oligodeoxynucleotides antisense to mRNA for specific integrins selectively attenuate mechanical hyperalgesia induced by specific proinflammatory cytokines [27,29,62,63,153]. One intriguing recent example is the demonstration that the extracellular proteoglycan, versican, an extracellular matrix molecule that binds isolectin B4 (IB4) on a sub-population of nociceptors [78,165], may be necessary for the transduction of low pH by those IB4-positive nociceptors [131]; in addition, the attenuation of versican levels selectively attenuates signaling in this population of nociceptors [29]. Another function of the extracellular matrix is its ability to concentrate specific molecules (chemokines and neurotrophic factors) to present them to their cell surface receptors. Related to nociceptor function, versican can concentrate the chemokine, monocyte chemoattractant protein 1 (MCP1) [27], the receptor for which is present on the IB4-positive subpopulation of nociceptors [28], to produce mechanical hyperalgesia. Whether specific integrins and extracellular matrix molecules can be used to categorize functional populations of nociceptors, in addition to the IB4-positive population, is an important unanswered question.

Other neurotrophic factors, most notably members of the glial cell line–derived neurotrophic factor (GDNF) family (ie, GDNF, artemin, neurturin and persephin [3,20]), whose cognate receptors (ie, GFR α_{1-4} [14,207]) are present on subpopulations of nociceptors, have been shown to be up-regulated in the setting of pain [19,67,95,233]. The possibility that populations of nociceptors may be eliminated, for example, by the neurotoxin saporin coupled to IB4, to selectively eliminate IB4-positive nociceptors [8,219,246], provides an intriguing prototype for an approach to the treatment of pain syndromes that are mediated by a subpopulation of nociceptors [16,125,144,213] while preserving protective responses to noxious, potentially tissue-injuring stimuli, necessary for the survival of the organism. This aspect of the cell biology of the nociceptor promises to provide insights into diverse pain syndromes as well as to provide targets for the treatment of currently intractable pain syndromes.

3. Cell contents

The concept of second messengers took root with the discovery of cyclic adenosine monophosphate (cAMP) [195], which subsequently was the first signaling molecule implicated in nociceptor sensitization [79,82]. This pathway is activated by a G-protein–coupled receptor coupled to a stimulatory G-protein (G α_s), which in turn activates adenylyl cyclase, leading to production of cAMP and the downstream activation of protein kinase A (PKA). PKA phosphorylates voltage-gated ion channels, regulating neuronal excitability [22,44,59]. Over time, several other second messengers, especially other kinases, have been implicated in nociceptor sensitization. Probably the next most well-studied second messenger in nociceptor sensitization is protein kinase C (PKC) [46,48,227]. However, why there are multiple second messengers capable of leading to nociceptor sensitization and how these signaling pathways might be involved in different pain syndromes by selectively affecting different populations of nociceptors or different ion channels and receptors [1,57,68,135,148] are just beginning to be elucidated. In this regard, it is worth noting that the epsilon isoform of PKC (PKC ϵ) is found in almost all dorsal root ganglion neurons, but its pain-related function operates only in a particular subpopulation of nociceptors. Thus,

PKC ϵ plays a role in the transition from acute to chronic pain, but only when it acts in the IB4-positive nociceptors [78].

Interaction between cAMP/PKA and PKC signaling pathways are just beginning to be elucidated. The recent discovery of an exchange protein activated by cAMP (EPAC), a cAMP-dependent guanine-nucleotide exchange factor [30,100], has provided 1 mechanism by which cAMP/PKA and PKC signaling pathways can interact. Further discussion of the interaction between cAMP/PKA and PKC signaling pathways will be deferred to the discussion of nociceptor neuroplasticity, a mechanism implicated in the transition from acute to chronic pain.

The role of cellular organelles is another cell-biological subject that is beginning to emerge in studies of nociceptor sensitization. Because of space limitations, we will restrict our discussion to the example of the role of mitochondria in the primary afferent nociceptor. Given the immense distance between the transduction mechanisms in the peripheral terminal of the nociceptor and its cell body, the function of the nociceptor is heavily dependent on machinery in its peripheral terminal, which, compared to the conducting axon, contains a very high abundance of mitochondria [98,159]. The regulation of intracellular Ca²⁺, aerobic energy metabolism, generation of reactive oxygen species, and apoptosis are but a few of the better-known mitochondrial functions [11,41,72]. Inhibitors of any of the 5 mitochondrial electron transport chain complexes inhibit pain in models of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) therapy, cancer therapy, and diabetic painful peripheral neuropathy [78,113,116]. Furthermore, caspase signaling in the apoptotic pathway as well as all 5 electron transport chain complexes have been implicated in hyperalgesia induced by TNF α and NGF [50,112]. In addition, mitochondria-derived reactive oxygen species and mitochondria-regulated intracellular calcium influence physiological and pathological nociceptor function [50,75,117,130,208,236]. The cell biology by which these various mitochondrial functions interact to produce nociceptor sensitization remains to be fully described. We have, however, recently provided evidence that mitochondrial fission, an important component of mitochondrial dynamics that regulates multiple mitochondrial functions, may provide a target for the treatment of neuropathic pain [77].

A more detailed elucidation of the intracellular mechanisms involved in nociceptor sensitization, a key component of diverse clinical pain syndromes [90,187,194], will likely provide insight into the complex intracellular molecular interactions producing the hypersensitive state and how disease states that alter cellular function may lead to clinical pain syndromes.

4. The plasma membrane of the cell: organized interaction of signaling molecules

Although most pain research being performed at the cellular level has focused on transducers and ion channels in the plasma membrane and on second messenger signaling pathways in the cytoplasm, it has not, until relatively recently, directed attention to higher-order organizational units in the cell such as the extracellular matrix, multi-molecular complexes in the plasma membrane (eg, lipid rafts and caveolae), and intracellular organelles in the cytoplasm (eg, mitochondria, Golgi apparatus, endoplasmic reticulum, and cytoskeleton) that, together, provide a framework for piecing together the puzzle of pain molecules. In this review, we explore the power that a more integrative cell biological approach provides to development of a fuller understanding of the neurobiology of pain. Building from the unitary domain (single molecules or pairs of molecules in linear signaling pathways) in classic studies of pain mechanisms, to the more complex multi-molecular

components of the cell, provides important insight into the organizational principles of the neurobiology of pain.

The classic view of the cell's plasma membrane was that of a lipid bilayer containing uniformly distributed signaling proteins. Thus, a thermal transducer might be a protein floating in the lipid membrane that had a high temperature coefficient for change in its molecular structure (Q10), producing a conducting pore for ions when a certain temperature in the environment is exceeded. In this view, sensitization reflected phosphorylation of voltage-gated ion channels in the membrane, such that a small depolarization produced by a transducer would be amplified, lowering the threshold for production of an action potential, which then propagates to the dorsal horn of the spinal cord. This simplified model of the plasma membrane of the primary afferent nociceptor has been immensely successful, and recent cell biological approaches to the system have added an additional level of nuance and complexity to our understanding of this membrane's structure and function.

Arguably, the most dramatic change in our view of the cell's plasma membrane has been the description of micro-domains that support very specific functions by bringing molecular elements of a signaling pathway together, and excluding members of other pathways, producing a highly efficient signaling complex or "signalosome" [104,175]. Structures such as lipid rafts contain elements necessary to execute specific signaling events, including nociceptor sensitization, by activation of a specific cell-surface receptor, and signaling to a specific second-messenger–signaling pathway. As an example, we have shown that integrins play a critical role in inflammatory pain by interacting with components of second messenger cascades [4,5,62,153]—from G-protein–coupled receptors to kinases—that mediate inflammatory hyperalgesia. Specifically, interactions with the cyclooxygenase product of arachidonic acid, prostaglandin E₂ (PGE₂), may be mediated by a signalosome organized by lipid rafts, as disrupting lipid rafts interrupts this signaling pathway [62].

Elucidation of other aspects of the cell biology of the nociceptor plasma membrane has suggested novel approaches to treat pain. As an example, it has long been known that certain viruses (eg, herpes simplex) can gain entry into a population of nociceptors, where they can continue to replicate [92]. Investigators have taken advantage of this bit of virological cell biology to create genetically engineered viruses that are able to produce molecules within the infected nociceptor that have the potential to attenuate nociceptor signaling and neurotransmission to the spinal cord [92,94,222,247]. The potential to selectively manipulate the function of the nociceptor without affecting other cells hints at the possibility of developing highly selective analgesic therapies, while minimizing their side effects.

5. Chronic pain

Most often one can find chronic pain defined as pain that has persisted for some period of time (eg, 1 month [111,152], 3 months [31,166], 6 months [53,136], or 12 months [229]), which is not, however, justified by any specific mechanism separating the acute and chronic phase of the pain syndrome. As a starting point, we propose that there are at least 2 mechanistically distinct types of chronic pain, which we will refer to as type I and type II. Type I chronic pain is here defined as acute pain that persists for a prolonged period of time. In contrast, type II chronic pain involves a mechanistic transition from the acute to the chronic phase of the pain syndrome. This transition involves the disconnection of the generation of pain by the initial tissue injury, and/or loss of responsiveness to therapies that successfully treat acute pain. Clinical observation supports this distinction: (1) patients who have experienced inflammatory pain for a prolonged period of time, such as patients with previously untreated rheumatoid arthritis, can experience dramatic relief of their pain by treatment with an inhibitor of the pronociceptive inflammatory mediator, TNF α [86] (type I

chronic pain), whereas (2) other patients who initially responded well to treatment, for example with NSAIDs, for osteoarthritis or rheumatoid arthritis, may then experience loss of efficacy over time [151,239] (type II chronic pain).

Of all the pieces of the pain puzzle, unraveling the mechanisms underlying the transition from acute to chronic pain has been 1 of the most challenging. We have described 1 candidate mechanism of neuronal plasticity in primary afferent nociceptive nerve fibers (nociceptors) by which an acute inflammatory insult or environmental stressor can trigger long-lasting hypersensitivity of nociceptors in response to a subsequent exposure to a low concentration of an inflammatory mediator. This phenomenon, which we have referred to as “hyperalgesic priming,” is dependent on activation of PKC ϵ and a switch in intracellular signaling pathways that mediates cytokine-induced nociceptor hyperexcitability from PKA alone to also include signaling via PKC ϵ [66,194]. Importantly, other mechanisms, in both the peripheral and central nervous systems, have also been implicated in the persistence of sensitized states. For example, Price [127], and McMahon [156] have provided evidence that chronic changes may also depend on the activity of protein kinase M ζ (PKM ζ), an essential mechanism in the neuroplasticity associated with late-phase long-term potentiation (LTP), a well-established memory mechanism [99,147].

6. Nociceptor sex

It is now well recognized that pain is sexually dimorphic, with differences between males and females demonstrated in multiple studies, in human diseases and animal models [55,83,93,124,145,155,164,196,215]. Both androgen and estrogen receptors, as well as synthetic pathways for sex hormones, have been found in pain circuits in the peripheral and central nervous system [60,73,149,218,244,250]. The primary afferent nociceptor has been shown to contain receptors for male and female sex hormones [71,123,178,245]. Many of the differences in pain between males and females are sex hormone dependent. For example, we have demonstrated that the second-messenger signaling pathways in nociceptors for induction of mechanical hyperalgesia is estrogen dependent [106]. Similarly, on the cellular level, estrogen can sensitize nociceptors by acting on the nociceptive neuron [132]. In sensory neurons, the action of estrogen can be rapid, occurring over a matter of seconds [143,161,167], implicating unknown actions beyond their classical actions on gene transcription. There remain many other unanswered questions related to fundamental aspects of sexual dimorphism in pain syndromes. For example, whereas it is known that females of multiple species have lower mechanical pain thresholds than males, we still do not know whether these differences are due to sexual dimorphism in mechanisms in the peripheral and/or central nervous system.

7. Looking forward

Although in this review we have summarized only a relatively small fraction of the growing literature on the cell biology of pain, and focused on the primary afferent nociceptor, we have attempted to demonstrate the power of cell biology in addressing key questions related to the neurobiology of pain, and to suggest ways in which this approach can enhance the development of novel treatments for currently intractable chronic pain syndromes.

Acknowledgments

The authors acknowledge cell biologists in the diverse fields of biomedical research whose contributions in their respective fields have been an unending source of inspiration for studies of the cell biology of pain. The authors' research discussed in this review was supported by the National Institutes of Health.

References

1. Abdel Samad O, Liu Y, Yang FC, Kramer I, Arber S, Ma Q. Characterization of two Runx1-dependent nociceptor differentiation programs necessary for inflammatory versus neuropathic pain. *Mol Pain*. 2010; 6:45. [PubMed: 20673362]
2. Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. *J Manag Care Pharm*. 2011; 17:S14–8. [PubMed: 22073935]
3. Airaksinen MS, Holm L, Hatanen T. Evolution of the GDNF family ligands and receptors. *Brain Behav Evol*. 2006; 68:181–90. [PubMed: 16912471]
4. Alessandri-Haber N, Dina OA, Joseph EK, Reichling DB, Levine JD. Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia. *J Neurosci*. 2008; 28:1046–57. [PubMed: 18234883]
5. Alessandri-Haber N, Dina OA, Yeh JJ, Parada CA, Reichling DB, Levine JD. Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat. *J Neurosci*. 2004; 24:4444–52. [PubMed: 15128858]
6. Aley KO, Levine JD. Role of protein kinase A in the maintenance of inflammatory pain. *J Neurosci*. 1999; 19:2181–6. [PubMed: 10066271]
7. Aloe L, Tuveri MA, Carcassi U, Levi-Montalcini R. Nerve growth factor in the synovial fluid of patients with chronic arthritis. *Arthritis Rheum*. 1992; 35:351–5. [PubMed: 1536673]
8. Alvarez P, Gear RW, Green PG, Levine JD. IB4-saporin attenuates acute and eliminates chronic muscle pain in the rat. *Exp Neurol*. 2012; 233:859–65. [PubMed: 22206923]
9. Anand P. Neurotrophins and peripheral neuropathy. *Philos Trans R Soc Lond B Biol Sci*. 1996; 351:449–54. [PubMed: 8730784]
10. Anand P. Neurotrophic factors and their receptors in human sensory neuropathies. *Prog Brain Res*. 2004; 146:477–92. [PubMed: 14699981]
11. Apostolova N, Blas-Garcia A, Esplugues JV. Mitochondria sentencing about cellular life and death: a matter of oxidative stress. *Curr Pharm Des*. 2011; 17:4047–60. [PubMed: 22188454]
12. Araki, M.; Aranami, T.; Matsuoka, T.; Nakamura, M.; Miyake, S.; Yamamura, T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. *Mod Rheumatol*. 2012. <http://dx.doi.org/10.1007/s10165-012-0715-9>
13. Aubdool AA, Brain SD. Neurovascular aspects of skin neurogenic inflammation. *J Investig Dermatol Symp Proc*. 2011; 15:33–9.
14. Baloh RH, Enomoto H, Johnson EMJ, Milbrandt J. The GDNF family ligands and receptors—implications for neural development. *Curr Opin Neurobiol*. 2000; 10:103–10. [PubMed: 10679429]
15. Baron R. Neuropathic pain: a clinical perspective. *Handb Exp Pharmacol*. 2009; 194:3–30. [PubMed: 19655103]
16. Basbaum, AI.; Braz, JM. Transgenic mouse models for the tracing of “pain” pathways. In: Kruger, L.; Light, AR., editors. *Translational pain research: from mouse to man*. Vol. Chapter 7. Boca Raton, FL: CRC Press; 2010.
17. Bautista DM, Movahed P, Hinman A, Axelsson HE, Sterner O, Hogestatt ED, Julius D, Jordt SE, Zygmunt PM. Pungent products from garlic activate the sensory ion channel TRPA1. *Proc Natl Acad Sci U S A*. 2005; 102:12248–52. [PubMed: 16103371]
18. Belmonte C, Viana F. Molecular and cellular limits to somatosensory specificity. *Mol Pain*. 2008; 4:14. [PubMed: 18419827]
19. Bennett DL, Michael GJ, Ramachandran N, Munson JB, Averill S, Yan Q, McMahon SB, Priestley JV. A distinct subgroup of small DRG cells express GDNF receptor components and GDNF is protective for these neurons after nerve injury. *J Neurosci*. 1998; 18:3059–72. [PubMed: 9526023]
20. Bessalov MM, Saarma M. GDNF family receptor complexes are emerging drug targets. *Trends Pharmacol Sci*. 2007; 28:68–74. [PubMed: 17218019]
21. Bessou P, Perl ER. Response of cutaneous sensory units with unmyelinated fibers to noxious stimuli. *J Neurophysiol*. 1969; 32:1025–43. [PubMed: 5347705]

22. Bevan S, Storey N. Modulation of sodium channels in primary afferent neurons. *Novartis Found Symp.* 2002; 241:144–53. discussion 153–158, 226–232. [PubMed: 11771643]
23. Bhawe G, Gereau RWt. Posttranslational mechanisms of peripheral sensitization. *J Neurobiol.* 2004; 61:88–106. [PubMed: 15362155]
24. Binshtok AM. Mechanisms of nociceptive transduction and transmission: a machinery for pain sensation and tools for selective analgesia. *Int Rev Neurobiol.* 2011; 97:143–77. [PubMed: 21708310]
25. Birdsong WT, Fierro L, Williams FG, Spelta V, Naves LA, Knowles M, Marsh-Haffner J, Adelman JP, Almers W, Elde RP, McCleskey EW. Sensing muscle ischemia: coincident detection of acid and ATP via interplay of two ion channels. *Neuron.* 2010; 68:739–49. [PubMed: 21092862]
26. Bogen O, Alessandri-Haber N, Chu C, Gear RW, Levine JD. Generation of a pain memory in the primary afferent nociceptor triggered by PKCepsilon activation of CPEB. *J Neurosci.* 2012; 32:2018–26. [PubMed: 22323716]
27. Bogen O, Dina OA, Gear RW, Levine JD. Dependence of monocyte chemoattractant protein 1 induced hyperalgesia on the isolectin B4-binding protein versican. *Neuroscience.* 2009; 159:780–6. [PubMed: 19167466]
28. Bogen O, Dreger M, Gillen C, Schroder W, Hucho F. Identification of versican as an isolectin B4-binding glycoprotein from mammalian spinal cord tissue. *FEBS J.* 2005; 272:1090–102. [PubMed: 15720384]
29. Bogen O, Joseph EK, Chen X, Levine JD. GDNF hyperalgesia is mediated by PLCgamma, MAPK/ERK, PI3K, CDK5 and Src family kinase signaling and dependent on the IB4-binding protein versican. *Eur J Neurosci.* 2008; 28:12–9. [PubMed: 18616564]
30. Borland G, Smith BO, Yarwood SJ. EPAC proteins transduce diverse cellular actions of cAMP. *Br J Pharmacol.* 2009; 158:70–86. [PubMed: 19210747]
31. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. *PAIN®.* 2008; 136:380–7. [PubMed: 17888574]
32. Braz JM, Basbaum AI. Differential ATF3 expression in dorsal root ganglion neurons reveals the profile of primary afferents engaged by diverse noxious chemical stimuli. *PAIN®.* 2010; 150:290–301. [PubMed: 20605331]
33. Braz JM, Nassar MA, Wood JN, Basbaum AI. Parallel “pain” pathways arise from subpopulations of primary afferent nociceptor. *Neuron.* 2005; 47:787–93. [PubMed: 16157274]
34. Brederson JD, Chu KL, Reilly RM, Brown BS, Kym PR, Jarvis MF, McGaraughty S. TRPV1 antagonist, A-889425, inhibits mechanotransmission in a subclass of rat primary afferent neurons following peripheral inflammation. *Synapse.* 2012; 66:187–95. [PubMed: 21953601]
35. Brierley SM. Molecular basis of mechanosensitivity. *Auton Neurosci.* 2010; 153:58–68. [PubMed: 19683967]
36. Brierley SM, Jones RCr, Xu L, Gebhart GF, Blackshaw LA. Activation of splanchnic and pelvic colonic afferents by bradykinin in mice. *Neurogastroenterol Motil.* 2005; 17:854–62. [PubMed: 16336501]
37. Brown DA, Passmore GM. Some new insights into the molecular mechanisms of pain perception. *J Clin Invest.* 2010; 120:1380–3. [PubMed: 20424321]
38. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. *J Pain.* 2012; 13:790–8. [PubMed: 22784777]
39. Burgess PR, Perl ER. Myelinated afferent fibres responding specifically to noxious stimulation of the skin. *J Physiol.* 1967; 190:541–62. [PubMed: 6051786]
40. Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). *Ann Rheum Dis.* 2011; 70:755–9. [PubMed: 21187298]
41. Cardoso AR, Queliconi BB, Kowaltowski AJ. Mitochondrial ion transport pathways: role in metabolic diseases. *Biochim Biophys Acta.* 2010; 1797:832–8. [PubMed: 20044972]

42. Caterina MJ. Transient receptor potential ion channels as participants in thermosensation and thermoregulation. *Am J Physiol Regul Integr Comp Physiol*. 2007; 292:R64–76. [PubMed: 16973931]
43. Cattaneo A. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. *Curr Opin Mol Ther*. 2010; 12:94–106. [PubMed: 20140821]
44. Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. *Neuron*. 2000; 26:13–25. [PubMed: 10798388]
45. Cervero F, Laird JM. Role of ion channels in mechanisms controlling gastrointestinal pain pathways. *Curr Opin Pharmacol*. 2003; 3:608–12. [PubMed: 14644012]
46. Cesare P, McNaughton P. Peripheral pain mechanisms. *Curr Opin Neurobiol*. 1997; 7:493–9. [PubMed: 9287200]
47. Chen SR, Cai YQ, Pan HL. Plasticity and emerging role of BKCa channels in nociceptive control in neuropathic pain. *J Neurochem*. 2009; 110:352–62. [PubMed: 19457113]
48. Cheng JK, Ji RR. Intracellular signaling in primary sensory neurons and persistent pain. *Neurochem Res*. 2008; 33:1970–8. [PubMed: 18427980]
49. Cho H, Yang YD, Lee J, Lee B, Kim T, Jang Y, Back SK, Na HS, Harfe BD, Wang F, Raouf R, Wood JN, Oh U. The calcium-activated chloride channel anoctamin 1 acts as a heat sensor in nociceptive neurons. *Nat Neurosci*. 2012; 15:1015–21. [PubMed: 22634729]
50. Chu C, Levine E, Gear RW, Bogen O, Levine JD. Mitochondrial dependence of nerve growth factor-induced mechanical hyperalgesia. *PAIN[®]*. 2011; 152:1832–7. [PubMed: 21570183]
51. Chung MK, Lee H, Mizuno A, Suzuki M, Caterina MJ. TRPV3 and TRPV4 mediate warmth-evoked currents in primary mouse keratinocytes. *J Biol Chem*. 2004; 279:21569–75. [PubMed: 15004014]
52. Clarke JN, Anderson RL, Haberberger RV, Gibbins IL. Non-peptidergic small diameter primary afferents expressing VGluT2 project to lamina I of mouse spinal dorsal horn. *Mol Pain*. 2011; 7:95. [PubMed: 22152428]
53. International Association for the Study of Pain Subcommittee on Taxonomy. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. *Pain Suppl*. 1986; 3:S1–S226. [PubMed: 3461421]
54. Coste B, Mathur J, Schmidt M, Earley TJ, Ranade S, Petrus MJ, Dubin AE, Patapoutian A. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. *Science*. 2010; 330:55–60. [PubMed: 20813920]
55. Craft RM, Mogil JS, Aloisi AM. Sex differences in pain and analgesia: the role of gonadal hormones. *Eur J Pain*. 2004; 8:397–411. [PubMed: 15324772]
56. Cruz-Orengo L, Dhaka A, Heuermann RJ, Young TJ, Montana MC, Cavanaugh EJ, Kim D, Story GM. Cutaneous nociception evoked by 15-delta PGJ2 via activation of ion channel TRPA1. *Mol Pain*. 2008; 4:30. [PubMed: 18671867]
57. Dabby R. Pain disorders and erythromelalgia caused by voltage-gated sodium channel mutations. *Curr Neurol Neurosci Rep*. 2012; 12:76–83. [PubMed: 21984269]
58. Dabiri BE, Lee H, Parker KK. A potential role for integrin signaling in mechanoelectrical feedback progress in biophysics and molecular biology. *Prog Biophys Mol Biol*. 2012
59. Dai S, Hall DD, Hell JW. Supramolecular assemblies and localized regulation of voltage-gated ion channels. *Physiol Rev*. 2009; 89:411–52. [PubMed: 19342611]
60. Deliu E, Brailoiu GC, Arterburn JB, Oprea TI, Benamar K, Dun NJ, Brailoiu E. Mechanisms of G protein-coupled estrogen receptor-mediated spinal nociception. *J Pain*. 2012; 13:742–54. [PubMed: 22858342]
61. Delmas P, Hao J, Rodat-Despoix L. Molecular mechanisms of mechanotransduction in mammalian sensory neurons. *Nat Rev Neurosci*. 2011; 12:139–53. [PubMed: 21304548]
62. Dina OA, Hucho T, Yeh J, Malik-Hall M, Reichling DB, Levine JD. Primary afferent second messenger cascades interact with specific integrin subunits in producing inflammatory hyperalgesia. *PAIN[®]*. 2005; 115:191–203. [PubMed: 15836982]
63. Dina OA, Parada CA, Yeh J, Chen X, McCarter GC, Levine JD. Integrin signaling in inflammatory and neuropathic pain in the rat. *Eur J Neurosci*. 2004; 19:634–42. [PubMed: 14984413]

64. Dina OA, Gear RW, Messing RO, Levine JD. Severity of alcohol-induced painful peripheral neuropathy in female rats: role of estrogen and protein kinase (A and Cepsilon). *Neuroscience*. 2007; 145:350–6. [PubMed: 17204374]
65. Dina OA, Green PG, Levine JD. Role of interleukin-6 in chronic muscle hyperalgesic priming. *Neuroscience*. 2008; 152:521–5. [PubMed: 18280048]
66. Dina OA, Khasar SG, Gear RW, Levine JD. Activation of Gi induces mechanical hyperalgesia poststress or inflammation. *Neuroscience*. 2009; 160:501–7. [PubMed: 19275929]
67. Dong ZQ, Ma F, Xie H, Wang YQ, Wu GC. Changes of expression of glial cell line-derived neurotrophic factor and its receptor in dorsal root ganglions and spinal dorsal horn during electroacupuncture treatment in neuropathic pain rats. *Neurosci Lett*. 2005; 376:143–8. [PubMed: 15698937]
68. Dubin AE, Patapoutian A. Nociceptors: the sensors of the pain pathway. *J Clin Invest*. 2010; 120:3760–72. [PubMed: 21041958]
69. Dussor G, Koerber HR, Oaklander AL, Rice FL, Molliver DC. Nucleotide signaling and cutaneous mechanisms of pain transduction. *Brain Res Rev*. 2009; 60:24–35. [PubMed: 19171165]
70. Eberhardt MJ, Filipovic MR, Leffler A, de la Roche J, Kistner K, Fischer MJ, Fleming T, Zimmermann K, Ivanovic-Burmazovic I, Nawroth PP, Bierhaus A, Reeh PW, Sauer SK. Methylglyoxal activates nociceptors through TRPA1—a possible mechanism of metabolic neuropathies. *J Biol Chem*. 2012; 287:28291–306. [PubMed: 22740698]
71. Fan X, Kim HJ, Warner M, Gustafsson JA. Estrogen receptor beta is essential for sprouting of nociceptive primary afferents and for morphogenesis and maintenance of the dorsal horn interneurons. *Proc Natl Acad Sci U S A*. 2007; 104:13696–701. [PubMed: 17693550]
72. Feissner RF, Skalska J, Gaum WE, Sheu SS. Crosstalk signaling between mitochondrial Ca^{2+} and ROS. *Front Biosci*. 2009; 14:1197–218.
73. Fenzi F, Rizzuto N. Estrogen receptors localization in the spinal trigeminal nucleus: an immunohistochemical study in humans. *Eur J Pain*. 2011; 15:1002–7. [PubMed: 21640622]
74. Fernandes ES, Fernandes MA, Keeble JE. The functions of TRPA1 and TRPV1: moving away from sensory nerves. *Br J Pharmacol*. 2012; 166:510–21. [PubMed: 22233379]
75. Fernyhough P, Calcutt NA. Abnormal calcium homeostasis in peripheral neuropathies. *Cell Calcium*. 2010; 47:130–9. [PubMed: 20034667]
76. Ferrari LF, Bogen O, Alessandri-Haber N, Levine E, Gear RW, Levine JD. Transient decrease in nociceptor GRK2 expression produces long-term enhancement in inflammatory pain. *Neuroscience*. 2012
77. Ferrari LF, Chum A, Bogen O, Reichling DB, Levine JD. Role of drp1, a key mitochondrial fission protein, in neuropathic pain. *J Neurosci*. 2011; 31:11404–10. [PubMed: 21813700]
78. Ferrari LF, Levine JD. Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms. *Eur J Neurosci*. 2010; 32:811–8. [PubMed: 20726883]
79. Ferreira SH. Local analgesic effect of morphine on the hyperalgesia induced by cAMP, Ca^{2+} , isoprenaline, and PGE2. *Adv Prostaglandin Thromboxane Res*. 1980; 8:1207–15. [PubMed: 6246772]
80. Ferreira SH. Peripheral analgesia: mechanism of the analgesic action of aspirin-like drugs and opiate-antagonists. *Br J Clin Pharmacol*. 1980; 10:237S–45S. [PubMed: 6254551]
81. Ferreira SH. Prostaglandins, pain, and inflammation. *Agents Actions Suppl*. 1986; 19:91–8. [PubMed: 3019112]
82. Ferreira SH, Nakamura M. I—Prostaglandin hyperalgesia, a cAMP/ Ca^{2+} dependent process. *Prostaglandins*. 1979; 18:179–90. [PubMed: 230542]
83. Fillingim RB, Ness TJ. Sex-related hormonal influences on pain and analgesic responses. *Neurosci Biobehav Rev*. 2000; 24:485–501. [PubMed: 10817845]
84. Finnerup NB, Sindrup SH, Jensen TS. Chronic neuropathic pain: mechanisms, drug targets and measurement. *Fundam Clin Pharmacol*. 2007; 21:129–36. [PubMed: 17391285]
85. Freeman DK, Fried SI. Multiple components of ganglion cell desensitization in response to prosthetic stimulation. *J Neural Eng*. 2011; 8:016008. [PubMed: 21248379]

86. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dorner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. *Ann Rheum Dis.* 2012; 71:i2–i45. [PubMed: 22460137]
87. Garrison SR, Stucky CL. The dynamic TRPA1 channel: a suitable pharmacological pain target? *Curr Pharm Biotechnol.* 2011; 12:1689–97. [PubMed: 21466445]
88. Gebhart GF. Peripheral contributions to visceral hyperalgesia. *Can J Gastroenterol.* 1999; 13:37A–41A. [PubMed: 10099815]
89. Gerhold KA, Bautista DM. Molecular and cellular mechanisms of trigeminal chemosensation. *Ann N Y Acad Sci.* 2009; 1170:184–9. [PubMed: 19686135]
90. Gold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. *Nat Med.* 2010; 16:1248–57. [PubMed: 20948530]
91. Gold MS, Levine JD. DAMGO inhibits prostaglandin E2-induced potentiation of a TTX-resistant Na^+ current in rat sensory neurons in vitro. *Neurosci Lett.* 1996; 212:83–6. [PubMed: 8832644]
92. Goss JR, Gold MS, Glorioso JC. HSV vector-mediated modification of primary nociceptor afferents: an approach to inhibit chronic pain. *Gene Ther.* 2009; 16:493–501. [PubMed: 19357694]
93. Greenspan JD, Craft RM, LeResche L, Arendt-Nielsen L, Berkley KJ, Fillingim RB, Gold MS, Holdcroft A, Lautenbacher S, Mayer EA, Mogil JS, Murphy AZ, Traub RJ. Studying sex and gender differences in pain and analgesia: a consensus report. *PAIN®.* 2007; 132:S26–45. [PubMed: 17964077]
94. Hao S, Wolfe D, Glorioso JC, Mata M, Fink DJ. Effects of transgene-mediated endomorphin-2 in inflammatory pain. *Eur J Pain.* 2009; 13:380–6. [PubMed: 18567517]
95. Harpf C, Dabernig J, Humpel C. Receptors for NGF and GDNF are highly expressed in human peripheral nerve neuroma. *Muscle Nerve.* 2002; 25:612–5. [PubMed: 11932982]
96. Heinzmann S, McMahon SB. New molecules for the treatment of pain. *Curr Opin Support Palliat Care.* 2011; 5:111–5. [PubMed: 21455071]
97. Hendrich J, Alvarez P, Chen X, Levine JD. GDNF induces mechanical hyperalgesia in muscle by reducing I(BK) in isolectin B4-positive nociceptors. *Neuroscience.* 2012; 219:204–13. [PubMed: 22704965]
98. Hensel H, Andres KH, von Düring M. Structure and function of cold receptors. *Pflügers Arch.* 1974; 352:1–10. [PubMed: 4475397]
99. Hirai T, Chida K. Protein kinase C ζ (PKC ζ): activation mechanisms and cellular functions. *J Biochem.* 2003; 133:1–7. [PubMed: 12761192]
100. Holz GG, Kang G, Harbeck M, Roe MW, Chepurny OG. Cell physiology of cAMP sensor Epac. *J Physiol.* 2006; 577:5–15. [PubMed: 16973695]
101. Holzer P. Acid-sensitive ion channels and receptors. *Handb Exp Pharmacol.* 2009; 283–332. [PubMed: 19655111]
102. Holzer P. Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system. *Pharmacol Ther.* 2011; 131:142–70. [PubMed: 21420431]
103. Hu, H.; Bandell, M.; Grandl, J.; Petrus, M. High-throughput approaches to studying mechanisms of TRP channel activation. In: Zhu, MX., editor. *TRP Channels*. Vol. Chapter 12. Boca Raton (FL): CRC Press; 2011. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK92822/>
104. Huber T, Sakmar TP. Escaping the flatlands: new approaches for studying the dynamic assembly and activation of GPCR signaling complexes. *Trends Pharmacol Sci.* 2011; 32:410–9. [PubMed: 21497404]
105. Hucho T, Levine JD. Signaling pathways in sensitization: toward a nociceptor cell biology. *Neuron.* 2007; 55:365–76. [PubMed: 17678851]
106. Hucho TB, Dina OA, Kuhn J, Levine JD. Estrogen controls PKC ϵ -dependent mechanical hyperalgesia through direct action on nociceptive neurons. *Eur J Neurosci.* 2006; 24:527–34. [PubMed: 16836642]
107. Hunt SP, Mantyh PW. The molecular dynamics of pain control. *Nat Rev Neurosci.* 2001; 2:83–91. [PubMed: 11252998]

108. Hwang SW, Oh U. Current concepts of nociception: nociceptive molecular sensors in sensory neurons. *Curr Opin Anaesthesiol.* 2007; 20:427–34. [PubMed: 17873595]
109. Jain A, Bronneke S, Kolbe L, Stab F, Wenck H, Neufang G. TRP-channel-specific cutaneous eicosanoid release patterns. *PAIN®.* 2011; 152:2765–72. [PubMed: 21962912]
110. Jankowski, MP.; Koerber, HR. Neurotrophic factors and nociceptor sensitization. In: Kruger, L.; Light, AR., editors. *Translational pain research: from mouse to man.* Boca Raton, FL: CRC Press; 2010. p. 31-49.
111. Johnson BW. Tutorial 23: mechanisms of chronic pain. *Pain Digest.* 1996; 6:97–108.
112. Joseph EK, Levine JD. Caspase signalling in neuropathic and inflammatory pain in the rat. *Eur J Neurosci.* 2004; 20:2896–902. [PubMed: 15579143]
113. Joseph EK, Levine JD. Mitochondrial electron transport in models of neuropathic and inflammatory pain. *PAIN®.* 2006; 121:105–14. [PubMed: 16472913]
114. Joseph EK, Parada CA, Levine JD. Hyperalgesic priming in the rat demonstrates marked sexual dimorphism. *PAIN®.* 2003; 105:143–50. [PubMed: 14499430]
115. Joseph EK, Bogen O, Alessandri-Haber N, Levine JD. PLC-beta 3 signals upstream of PKC epsilon in acute and chronic inflammatory hyperalgesia. *PAIN®.* 2007; 132:67–73. [PubMed: 17350763]
116. Joseph EK, Levine JD. Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. *J Pain.* 2009; 10:534–41. [PubMed: 19231296]
117. Joseph EK, Levine JD. Multiple PKCepsilon-dependent mechanisms mediating mechanical hyperalgesia. *PAIN®.* 2010; 150:17–21. [PubMed: 20456866]
118. Joseph EK, Levine JD. Hyperalgesic priming is restricted to isolectin B4-positive nociceptors. *Neuroscience.* 2010; 169:431–5. [PubMed: 20457222]
119. Kaszas K, Keller JM, Coddou C, Mishra SK, Hoon MA, Stojilkovic S, Jacobson KA, Iadarola MJ. Small molecule positive allosteric modulation of TRPV1 activation by vanilloids and acidic pH. *J Pharmacol Exp Ther.* 2012; 340:152–60. [PubMed: 22005042]
120. Kato A, Touhara K. Mammalian olfactory receptors: pharmacology, G protein coupling and desensitization. *Cell Mol Life Sci.* 2009; 66:3743–53. [PubMed: 19652915]
121. Katz N, Borenstein DG, Birbara C, Bramson C, Nemeth MA, Smith MD, Brown MT. Efficacy and safety of tanezumab in the treatment of chronic low back pain. *PAIN®.* 2011; 152:2248–58. [PubMed: 21696889]
122. Kawabata A. Prostaglandin E2 and pain—an update. *Biol Pharm Bull.* 2011; 34:1170–3. [PubMed: 21804201]
123. Keast JR, Gleeson RJ. Androgen receptor immunoreactivity is present in primary sensory neurons of male rats. *Neuroreport.* 1998; 9:4137–40. [PubMed: 9926862]
124. Khasar SG, Green PG, Levine JD. Repeated sound stress enhances inflammatory pain in the rat. *PAIN®.* 2005; 116:79–86. [PubMed: 15936144]
125. Kiasalari Z, Salehi I, Zhong Y, McMahon SB, Michael-Titus AT, Michael GJ. Identification of perineal sensory neurons activated by innocuous heat. *J Comp Neurol.* 2010; 518:137–62. [PubMed: 19937707]
126. Kim YH, Back SK, Davies AJ, Jeong H, Jo HJ, Chung G, Na HS, Bae YC, Kim SJ, Kim JS, Jung SJ, Oh SB. TRPV1 in GABAergic interneurons mediates neuropathic mechanical allodynia and disinhibition of the nociceptive circuitry in the spinal cord. *Neuron.* 2012; 74:640–7. [PubMed: 22632722]
127. King T, Qu C, Okun A, Melemedjian OK, Mandell EK, Maskaykina IY, Navratilova E, Dussor GO, Ghosh S, Price TJ, Porreca F. Contribution of PKMzeta-dependent and independent amplification to components of experimental neuropathic pain. *PAIN®.* 2012; 153:1263–73. [PubMed: 22482911]
128. Knecht M, Hummel T. Recording of the human electro-olfactogram. *Physiol Behav.* 2004; 83:13–9. [PubMed: 15501486]
129. Koltzenburg M. The changing sensitivity in the life of the nociceptor. *PAIN®.* 1999; (Suppl 1):S93–S102. [PubMed: 10491977]

130. Kostyuk E, Svichar N, Shishkin V, Kostyuk P. Role of mitochondrial dysfunction in calcium signalling alterations in dorsal root ganglion neurons of mice with experimentally-induced diabetes. *Neuroscience*. 1999; 90:535–41. [PubMed: 10215157]
131. Kubo A, Katanosaka K, Mizumura K. Extracellular matrix proteoglycan plays a pivotal role in sensitization by low pH of mechanosensitive currents in nociceptive sensory neurones. *J Physiol*. 2012; 590:2995–3007. [PubMed: 22570376]
132. Kuhn J, Dina OA, Goswami C, Suckow V, Levine JD, Hucho T. GPR30 estrogen receptor agonists induce mechanical hyperalgesia in the rat. *Eur J Neurosci*. 2008; 27:1700–9. [PubMed: 18371086]
133. Kumar S, Ruchi R, James SR, Chidiac EJ. Gene therapy for chronic neuropathic pain: how does it work and where do we stand today? *Pain Med*. 2011; 12:808–22. [PubMed: 21564510]
134. Kwan KY, Glazer JM, Corey DP, Rice FL, Stucky CL. TRPA1 modulates mechanotransduction in cutaneous sensory neurons. *J Neurosci*. 2009; 29:4808–19. [PubMed: 19369549]
135. Lampert A, O'Reilly AO, Reeh P, Leffler A. Sodium channelopathies and pain. *Pflugers Arch*. 2010; 460:249–63. [PubMed: 20101409]
136. Landmark T, Romundstad P, Dale O, Borchgrevink PC, Kaasa S. Estimating the prevalence of chronic pain: validation of recall against longitudinal reporting (the HUNT pain study). *PAIN®*. 2012; 153:1368–73. [PubMed: 22575226]
137. Leamy AW, Shukla P, McAlexander MA, Carr MJ, Ghatta S. Curcumin ((E, E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) activates and desensitizes the nociceptor ion channel TRPA1. *Neurosci Lett*. 2011; 503:157–62. [PubMed: 21855605]
138. Lechner SG, Lewin GR. Peripheral sensitisation of nociceptors via G-protein-dependent potentiation of mechanotransduction currents. *J Physiol*. 2009; 587:3493–503. [PubMed: 19505980]
139. Lee J, Chung MK, Ro JY. Activation of NMDA receptors leads to phosphorylation of TRPV1 S800 by protein kinase C and A-kinase anchoring protein 150 in rat trigeminal ganglia. *Biochem Biophys Res Commun*. 2012; 424:358–63. [PubMed: 22789851]
140. Lee J, Saloman JL, Weiland G, Auh QS, Chung MK, Ro JY. Functional interactions between NMDA receptors and TRPV1 in trigeminal sensory neurons mediate mechanical hyperalgesia in the rat masseter muscle. *PAIN®*. 2012; 153:1514–24. [PubMed: 22609428]
141. Leininger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. *J Peripher Nerv Syst*. 2004; 9:26–53. [PubMed: 14871451]
142. Leung YY, Bensmaia SJ, Hsiao SS, Johnson KO. Time-course of vibratory adaptation and recovery in cutaneous mechanoreceptive afferents. *J Neurophysiol*. 2005; 94:3037–45. [PubMed: 16222071]
143. Levin ER. Cellular functions of plasma membrane estrogen receptors. *Steroids*. 2002; 67:471–5. [PubMed: 11960623]
144. Levine JD, Alessandri-Haber N. TRP channels: targets for the relief of pain. *Biochim Biophys Acta*. 2007; 1772:989–1003. [PubMed: 17321113]
145. Levine JD, Khasar SG, Green PG. Neurogenic inflammation and arthritis. *Ann N Y Acad Sci*. 2006; 1069:155–67. [PubMed: 16855143]
146. Lewin GR, Ritter AM, Mendell LM. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. *J Neurosci*. 1993; 13:2136–48. [PubMed: 8478693]
147. Ling DS, Benardo LS, Serrano PA, Blace N, Kelly MT, Crary JF, Sacktor TC. Protein kinase Mzeta is necessary and sufficient for LTP maintenance. *Nat Neurosci*. 2002; 5:295–6. [PubMed: 11914719]
148. Liu Y, Ma Q. Generation of somatic sensory neuron diversity and implications on sensory coding. *Curr Opin Neurobiol*. 2011; 21:52–60. [PubMed: 20888752]
149. Loyd DR, Murphy AZ. Androgen and estrogen (alpha) receptor localization on periaqueductal gray neurons projecting to the rostral ventromedial medulla in the male and female rat. *J Chem Neuroanat*. 2008; 36:216–26. [PubMed: 18771723]
150. Lumpkin EA, Caterina MJ. Mechanisms of sensory transduction in the skin. *Nature*. 2007; 445:858–65. [PubMed: 17314972]

151. Luong BT, Chong BS, Lowder DM. Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab. *Ann Pharmacother.* 2000; 34:743–60. [PubMed: 10860137]
152. Maciver D, Jones D, Nicol M. Parents' experiences of caring for a child with chronic pain. *Qual Health Res.* 2010; 20:1272–82. [PubMed: 20406993]
153. Malik-Hall M, Dina OA, Levine JD. Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia. *Eur J Neurosci.* 2005; 21:3387–94. [PubMed: 16026476]
154. Malin SA, Christianson JA, Bielefeldt K, Davis BM. TPRV1 expression defines functionally distinct pelvic colon afferents. *J Neurosci.* 2009; 29:743–52. [PubMed: 19158300]
155. Manson JE. Pain: sex differences and implications for treatment. *Metabolism.* 2010; 59:S16–20. [PubMed: 20837187]
156. Marchand F, D'Mello R, Yip PK, Calvo M, Muller E, Pezet S, Dickenson AH, McMahon SB. Specific involvement of atypical PKCzeta/PKMzeta in spinal persistent nociceptive processing following peripheral inflammation in rat. *Mol Pain.* 2011; 7:86. [PubMed: 22054645]
157. Martin HA, Basbaum AI, Kwiat GC, Goetzl EJ, Levine JD. Leukotriene and prostaglandin sensitization of cutaneous high-threshold C- and A-delta mechanonociceptors in the hairy skin of rat hindlimbs. *Neuroscience.* 1987; 22:651–9. [PubMed: 2823177]
158. Martin YB, Herradon G, Ezquerro L. Uncovering new pharmacological targets to treat neuropathic pain by understanding how the organism reacts to nerve injury. *Curr Pharm Des.* 2011; 17:434–48. [PubMed: 21375486]
159. Messlinger K. Functional morphology of nociceptive and other fine sensory endings (free nerve endings) in different tissues. *Prog Brain Res.* 1996; 113:273–98. [PubMed: 9009741]
160. Meyer RA, Davis KD, Cohen RH, Treede RD, Campbell JN. Mechanically insensitive afferents (MIAs) in cutaneous nerves of monkey. *Brain Res.* 1991; 561:252–61. [PubMed: 1802341]
161. Micevych P, Christensen A. Membrane-initiated estradiol actions mediate structural plasticity and reproduction. *Front Neuroendocrinol.* 2012; 33:331–41. [PubMed: 22828999]
162. Mizumura K, Sugiura T, Katanosaka K, Banik RK, Kozaki Y. Excitation and sensitization of nociceptors by bradykinin: what do we know? *Exp Brain Res.* 2009; 196:53–65. [PubMed: 19396590]
163. Mo G, Grant R, O'Donnell D, Ragsdale DS, Cao CQ, Seguela P. Neuropathic Nav1.3-mediated sensitization to P2X activation is regulated by protein kinase C. *Mol Pain.* 2011; 7:14. [PubMed: 21314936]
164. Mogil JS, Chesler EJ, Wilson SG, Juraska JM, Sternberg WF. Sex differences in thermal nociception and morphine antinociception in rodents depend on genotype. *Neurosci Biobehav Rev.* 2000; 24:375–89. [PubMed: 10781697]
165. Molliver DC, Wright DE, Leitner ML, Parsadanian AS, Doster K, Wen D, Yan Q, Snider WD. IB4-binding DRG neurons switch from NGF to GDNF dependence in early postnatal life. *Neuron.* 1997; 19:849–61. [PubMed: 9354331]
166. Nachemson AL, Andersson GB. Classification of low-back pain. *Scand J Work Environ Health.* 1982; 8:134–6. [PubMed: 6215709]
167. Nadal A, Diaz M, Valverde MA. The estrogen trinity: membrane, cytosolic, and nuclear effects. *News Physiol Sci.* 2001; 16:251–5. [PubMed: 11719599]
168. Nagata K, Duggan A, Kumar G, Garcia-Anoveros J. Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing. *J Neurosci.* 2005; 25:4052–61. [PubMed: 15843607]
169. Nelson MT, Todorovic SM. Is there a role for T-type calcium channels in peripheral and central pain sensitization? *Mol Neurobiol.* 2006; 34:243–8. [PubMed: 17308355]
170. Noel J, Zimmermann K, Busserolles J, Deval E, Alloui A, Diochot S, Guy N, Borsotto M, Reeh P, Eschalier A, Lazdunski M. The mechano-activated K⁺ channels TRAAK and TREK-1 control both warm and cold perception. *EMBO J.* 2009; 28:1308–18. [PubMed: 19279663]
171. Numazaki M, Tominaga M. Nociception and TRP Channels. *Curr Drug Targets CNS Neurol Disord.* 2004; 3:479–85. [PubMed: 15578965]
172. Obata K, Noguchi K. BDNF in sensory neurons and chronic pain. *Neurosci Res.* 2006; 55:1–10. [PubMed: 16516994]

173. Ohta T, Imagawa T, Ito S. Novel gating and sensitizing mechanism of capsaicin receptor (TRPV1): tonic inhibitory regulation of extracellular sodium through the external protonation sites on TRPV1. *J Biol Chem.* 2008; 283:9377–87. [PubMed: 18230619]
174. Ossipov MH. Growth factors and neuropathic pain. *Curr Pain Headache Rep.* 2011; 15:185–92. [PubMed: 21327569]
175. Ostrom RS, Bogard AS, Gros R, Feldman RD. Choreographing the adenylyl cyclase signalosome: sorting out the partners and the steps. *Naunyn Schmiedebergs Arch Pharmacol.* 2012; 385:5–12. [PubMed: 22012074]
176. Otten U, Ruegg UT, Hill RC, Businger F, Peck M. Correlation between substance P content of primary sensory neurones and pain sensitivity in rats exposed to antibodies to nerve growth factor. *Eur J Pharmacol.* 1982; 85:351–3. [PubMed: 6185353]
177. Owyang AM, Issafras H, Corbin J, Ahluwalia K, Larsen P, Pongo E, Handa M, Horwitz AH, Roell MK, Haak-Frendscho M, Masat L. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1 β -mediated diseases. *MAbs.* 2011; 3:49–60. [PubMed: 21048425]
178. Papka RE, Srinivasan B, Miller KE, Hayashi S. Localization of estrogen receptor protein and estrogen receptor messenger RNA in peripheral autonomic and sensory neurons. *Neuroscience.* 1997; 79:1153–63. [PubMed: 9219974]
179. Parada CA, Reichling DB, Levine JD. Chronic hyperalgesic priming in the rat involves a novel interaction between cAMP and PKC ϵ second messenger pathways. *PAIN[®].* 2005; 113:185–90. [PubMed: 15621379]
180. Parada CA, Yeh JJ, Joseph EK, Levine JD. Tumor necrosis factor receptor type-1 in sensory neurons contributes to induction of chronic enhancement of inflammatory hyperalgesia in rat. *Eur J Neurosci.* 2003; 17:1847–52. [PubMed: 12752784]
181. Parada CA, Yeh JJ, Reichling DB, Levine JD. Transient attenuation of protein kinase C ϵ can terminate a chronic hyperalgesic state in the rat. *Neuroscience.* 2003; 120:219–26. [PubMed: 12849754]
182. Passmore GM, Reilly JM, Thakur M, Keasberry VN, Marsh SJ, Dickenson AH, Brown DA. Functional significance of M-type potassium channels in nociceptive cutaneous sensory endings. *Front Mol Neurosci.* 2012; 5:63. [PubMed: 22593734]
183. Patapoutian A, Tate S, Woolf CJ. Transient receptor potential channels: targeting pain at the source. *Nat Rev Drug Discov.* 2009; 8:55–68. [PubMed: 19116627]
184. Peng H, Lewandrowski U, Muller B, Sickmann A, Walz G, Wegierski T. Identification of a protein kinase C-dependent phosphorylation site involved in sensitization of TRPV4 channel. *Biochem Biophys Res Commun.* 2010; 391:1721–5. [PubMed: 20043876]
185. Perl ER. Cutaneous polymodal receptors: characteristics and plasticity. *Prog Brain Res.* 1996; 113:21–37. [PubMed: 9009726]
186. Perl ER. Myelinated afferent fibres innervating the primate skin and their response to noxious stimuli. *J Physiol.* 1968; 197:593–615. [PubMed: 4969883]
187. Perl ER. Pain mechanisms: a commentary on concepts and issues. *Prog Neurobiol.* 2011; 94:20–38. [PubMed: 21419824]
188. Perl ER, Kumazawa T, Lynn B, Kenins P. Sensitization of high threshold receptors with unmyelinated (C) afferent fibers. *Prog Brain Res.* 1976; 43:263–77. [PubMed: 815956]
189. Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. *Annu Rev Neurosci.* 2006; 29:507–38. [PubMed: 16776595]
190. Plant LD. A role for K2P channels in the operation of somatosensory nociceptors. *Front Mol Neurosci.* 2012; 5:21. [PubMed: 22403526]
191. Radovits BJ, Kievit W, Laan RF. Tumour necrosis factor- α antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety. *Drugs Aging.* 2009; 26:647–64. [PubMed: 19685931]
192. Radtke C, Sinis N, Sauter M, Jahn S, Kraushaar U, Guenther E, Rodemann HP, Rennekampff HO. TRPV channel expression in human skin and possible role in thermally induced cell death. *J Burn Care Res.* 2011; 32:150–9. [PubMed: 21099694]

193. Rau KK, McIlwrath SL, Wang H, Lawson JJ, Jankowski MP, Zylka MJ, Anderson DJ, Koerber HR. Mrgprd enhances excitability in specific populations of cutaneous murine polymodal nociceptors. *J Neurosci.* 2009; 29:8612–9. [PubMed: 19571152]
194. Reichling DB, Levine JD. Critical role of nociceptor plasticity in chronic pain. *Trends Neurosci.* 2009; 32:611–8. [PubMed: 19781793]
195. Robison GA, Butcher RW, Sutherland EW. Cyclic AMP. *Annu Rev Biochem.* 1968; 37:149–74. [PubMed: 4299844]
196. Rollman GB, Lautenbacher S. Sex differences in musculoskeletal pain. *Clin J Pain.* 2001; 17:20–4. [PubMed: 11289085]
197. Roza C, Reeh PW. Substance P, calcitonin gene related peptide and PGE2 co-released from the mouse colon: a new model to study nociceptive and inflammatory responses in viscera, in vitro. *PAIN®.* 2001; 93:213–9. [PubMed: 11514080]
198. Ruggieri V, Milizia M. Tickle perception as micro-experience of pleasure: its phenomenology on different areas of the body and relation to cerebral dominance. *Percept Mot Skills.* 1983; 56:903–14. [PubMed: 6877978]
199. Rukwied R, Dusch M, Schley M, Forsch E, Schmelz M. Nociceptor sensitization to mechanical and thermal stimuli in pig skin in vivo. *Eur J Pain.* 2008; 12:242–50. [PubMed: 17611131]
200. Rukwied R, Schley M, Forsch E, Obreja O, Dusch M, Schmelz M. Nerve growth factor-evoked nociceptor sensitization in pig skin in vivo. *J Neurosci Res.* 2010; 88:2066–72. [PubMed: 20143422]
201. Sah DW, Ossipov MH, Rossomando A, Silvian L, Porreca F. New approaches for the treatment of pain: the GDNF family of neurotrophic growth factors. *Curr Top Med Chem.* 2005; 5:577–83. [PubMed: 16022680]
202. Schaible HG, Ebersberger A, Natura G. Update on peripheral mechanisms of pain: beyond prostaglandins and cytokines. *Arthritis Res Ther.* 2011; 13:210. [PubMed: 21542894]
203. Schepers RJ, Ringkamp M. Thermoreceptors and thermosensitive afferents. *Neurosci Biobehav Rev.* 2009; 33:205–12. [PubMed: 18761036]
204. Schmelz M. Neuronal sensitivity of the skin. *Eur J Dermatol.* 2011; 21:43–7. [PubMed: 21628129]
205. Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjork HE, Handwerker HO. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. *J Neurophysiol.* 2003; 89:2441–8. [PubMed: 12611975]
206. Schmidt R, Schmelz M, Forster C, Ringkamp M, Torebjork E, Handwerker H. Novel classes of responsive and unresponsive C nociceptors in human skin. *J Neurosci.* 1995; 15:333–41. [PubMed: 7823139]
207. Scott RP, Ibanez CF. Determinants of ligand binding specificity in the glial cell line-derived neurotrophic factor family receptor alpha S. *J Biol Chem.* 2001; 276:1450–8. [PubMed: 11018032]
208. Shishkin V, Potapenko E, Kostyuk E, Girnyk O, Voitenko N, Kostyuk P. Role of mitochondria in intracellular calcium signaling in primary and secondary sensory neurones of rats. *Cell Calcium.* 2002; 32:121–30. [PubMed: 12208232]
209. Shu XQ, Mendell LM. Neurotrophins and hyperalgesia. *Proc Natl Acad Sci U S A.* 1999; 96:7693–6. [PubMed: 10393882]
210. Sisignano M, Park CK, Angioni C, Zhang DD, von Hehn C, Cobos EJ, Ghasemlou N, Xu ZZ, Kumaran V, Lu R, Grant A, Fischer MJ, Schmidtko A, Reeh P, Ji RR, Woolf CJ, Geisslinger G, Scholich K, Brenneis C. 5,6-EET is released upon neuronal activity and induces mechanical pain hypersensitivity via TRPA1 on central afferent terminals. *J Neurosci.* 2012; 32:6364–72. [PubMed: 22553041]
211. Snider WD, McMahon SB. Tackling pain at the source: new ideas about nociceptors. *Neuron.* 1998; 20:629–32. [PubMed: 9581756]
212. Stucky CL, Dubin AE, Jeske NA, Malin SA, McKemy DD, Story GM. Roles of transient receptor potential channels in pain. *Brain Res Rev.* 2009; 60:2–23. [PubMed: 19203589]
213. Stucky CL, Gold MS, Zhang X. Mechanisms of pain. *Proc Natl Acad Sci U S A.* 2001; 98:11845–6. [PubMed: 11562504]

214. Stucky CL, Lewin GR. Isolectin B(4)-positive and -negative nociceptors are functionally distinct. *J Neurosci*. 1999; 19:6497–505. [PubMed: 10414978]
215. Sun LS. Gender differences in pain sensitivity and responses to analgesia. *J Gend Specif Med*. 1998; 1:28–30. [PubMed: 11279850]
216. Taiwo YO, Levine JD. Effects of cyclooxygenase products of arachidonic acid metabolism on cutaneous nociceptive threshold in the rat. *Brain Res*. 1990; 537:372–4. [PubMed: 2128200]
217. Tam Tam S, Bastian I, Zhou XF, Vander Hoek M, Michael MZ, Gibbins IL, Haberberger RV. MicroRNA-143 expression in dorsal root ganglion neurons. *Cell Tissue Res*. 2011; 346:163–73. [PubMed: 22048787]
218. Tashiro A, Okamoto K, Bereiter DA. Rapid estrogenic effects on TMJ-responsive brainstem neurons. *J Dent Res*. 2012; 91:210–4. [PubMed: 22058119]
219. Taylor AM, Osikowicz M, Ribeiro-da-Silva A. Consequences of the ablation of nonpeptidergic afferents in an animal model of trigeminal neuropathic pain. *PAIN®*. 2012; 153:1311–9. [PubMed: 22521917]
220. Tominaga, M. The role of TRP channels in thermosensation. In: Liedtke, WB.; Heller, S., editors. *TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades*. Vol. Chapter 20. Boca Raton (FL): CRC Press; 2007. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK5244/>
221. Torebjork HE, Afferent C. Units responding to mechanical, thermal and chemical stimuli in human non-glabrous skin. *Acta Physiol Scand*. 1974; 92:374–90. [PubMed: 4141858]
222. Towne C, Pertin M, Beggah AT, Aebischer P, Decosterd I. Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. *Mol Pain*. 2009; 5:52. [PubMed: 19737386]
223. Travis J. Mysteries of the cell. How does the cell position its proteins? *Science*. 2011; 334:1048–9. [PubMed: 22116855]
224. Tsuda M, Tozaki-Saitoh H, Inoue K. Pain and purinergic signaling. *Brain Res Rev*. 2010; 63:222–32. [PubMed: 19931560]
225. Tuveri MA, Passiu G, Mathieu A, Aloe L. Nerve growth factor and mast cell distribution in the skin of patients with systemic sclerosis. *Clin Exp Rheumatol*. 1993; 11:319–22. [PubMed: 8353988]
226. Tyers MB, Haywood H. Effects of prostaglandins on peripheral nociceptors in acute inflammation. *Agents Actions Suppl*. 1979:65–78. [PubMed: 294149]
227. Velazquez KT, Mohammad H, Sweitzer SM. Protein kinase C in pain: involvement of multiple isoforms. *Pharmacol Res*. 2007; 55:578–89. [PubMed: 17548207]
228. Venstrom KA, Reichardt LF. Extracellular matrix. 2: role of extracellular matrix molecules and their receptors in the nervous system. *FASEB J*. 1993; 7:996–1003. [PubMed: 8370483]
229. VonKorff M. Studying the natural history of back pain. *Spine (Phila Pa 1976)*. 1994; 19:2041S–6S. [PubMed: 7801181]
230. Vongtau HO, Lavoie EG, Sevigny J, Molliver DC. Distribution of ecto-nucleotidases in mouse sensory circuits suggests roles for nucleoside triphosphate diphosphohydrolase-3 in nociception and mechanoreception. *Neuroscience*. 2011; 193:387–98. [PubMed: 21807070]
231. Walder RY, Radhakrishnan R, Loo L, Rasmussen LA, Mohapatra DP, Wilson SP, Sluka KA. TRPV1 is important for mechanical and heat sensitivity in uninjured animals and development of heat hypersensitivity after muscle inflammation. *PAIN®*. 2012; 153:1664–72. [PubMed: 22694790]
232. Wang H, Woolf CJ. Pain TRPs. *Neuron*. 2005; 46:9–12. [PubMed: 15820689]
233. Wang T, Molliver DC, Jing X, Schwartz ES, Yang FC, Samad OA, Ma Q, Davis BM. Phenotypic switching of nonpeptidergic cutaneous sensory neurons following peripheral nerve injury. *PLoS One*. 2011; 6:e28908. [PubMed: 22216140]
234. Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? *BioDrugs*. 2008; 22:349–59. [PubMed: 18998753]
235. Wei T, Guo TZ, Li WW, Hou S, Kingery W, Clark JD. Keratinocyte expression of inflammatory mediators plays a crucial role in substance P-induced acute and chronic pain. *J Neuroinflammation*. 2012; 9:181. [PubMed: 22824437]

236. Werth JL, Zhou B, Nutter LM, Thayer SA. 2',3'-Dideoxycytidine alters calcium buffering in cultured dorsal root ganglion neurons. *Mol Pharmacol.* 1994; 45:1119–24. [PubMed: 8022405]
237. Willis WD. Role of neurotransmitters in sensitization of pain responses. *Ann N Y Acad Sci.* 2001; 933:142–56. [PubMed: 12000017]
238. Willis WDJ. The role of TRPV1 receptors in pain evoked by noxious thermal and chemical stimuli. *Exp Brain Res.* 2009; 196:5–11. [PubMed: 19294370]
239. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. *Baillieres Clin Rheumatol.* 1995; 9:619–32. [PubMed: 8591645]
240. Wood JN, Abrahamsen B, Baker MD, Boorman JD, Donier E, Drew LJ, Nassar MA, Okuse K, Seereeram A, Stirling CL, Zhao J. Ion channel activities implicated in pathological pain. *Novartis Found Symp.* 2004; 261:32–40. discussion 40–54. [PubMed: 15469043]
241. Woolf CJ, Ma Q. Nociceptors—noxious stimulus detectors. *Neuron.* 2007; 55:353–64. [PubMed: 17678850]
242. Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. *Neuroscience.* 1994; 62:327–31. [PubMed: 7530342]
243. Wu X, Reddy DS. Integrins as receptor targets for neurological disorders. *Pharmacol Ther.* 2012; 134:68–81. [PubMed: 22233753]
244. Xiao, X.; Yang, Y.; Zhang, Y.; Zhang, XM.; Zhao, ZQ.; Zhang, YQ. Estrogen in the anterior cingulate cortex contributes to pain-related aversion. *Cereb Cortex.* 2012. <http://dx.doi.org/10.1093/cercor/bhs201>
245. Xu S, Cheng Y, Keast JR, Osborne PB. 17beta-Estradiol activates estrogen receptor beta-signalling and inhibits transient receptor potential vanilloid receptor 1 activation by capsaicin in adult rat nociceptor neurons. *Endocrinology.* 2008; 149:5540–8. [PubMed: 18617618]
246. Ye Y, Dang D, Viet CT, Dolan JC, Schmidt BL. Analgesia targeting IB4-positive neurons in cancer-induced mechanical hypersensitivity. *J Pain.* 2012; 13:524–31. [PubMed: 22483679]
247. Yeomans DC, Lu Y, Laurito CE, Peters MC, Vota-Vellis G, Wilson SP, Pappas GD. Recombinant herpes vector-mediated analgesia in a primate model of hyperalgesia. *Mol Ther.* 2006; 13:589–97. [PubMed: 16288901]
248. Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. *EMBO J.* 2005; 24:4211–23. [PubMed: 16319926]
249. Zhang XL, Mok LP, Katz EJ, Gold MS. BKCa currents are enriched in a subpopulation of adult rat cutaneous nociceptive dorsal root ganglion neurons. *Eur J Neurosci.* 2010; 31:450–62. [PubMed: 20105244]
250. Zhang Y, Xiao X, Zhang XM, Zhao ZQ, Zhang YQ. Estrogen facilitates spinal cord synaptic transmission via membrane-bound estrogen receptors: implications for pain hypersensitivity. *J Biol Chem.* 2012; 287:33268–81. [PubMed: 22869379]
251. Zylka MJ, Rice FL, Anderson DJ. Topographically distinct epidermal nociceptive circuits revealed by axonal tracers targeted to Mrgprd. *Neuron.* 2005; 45:17–25. [PubMed: 15629699]